Biosimilars Sandoz, the generics subsidiary of Swiss pharma major Novartis, has today released Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's Neupogen (filgrastim) in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy. 8 December 2014